Xspray Pharma

Declaration of Voting Results & Voting Rights Announcements • Dec 29, 2023

New number of shares and votes in Xspray Pharma

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the number of shares and votes in Xspray Pharma AB has changed as a result of shares being registered due to the exercise of warrants series TO5 which were issued in connection with the rights issue in June this year, and for which the subscription period ended on November 30.

Through the exercise of warrants series TO5 to subscribe for new shares, the number of outstanding shares and votes has increased by 2,307,242, from 28,946,300 to 31,253,542. The share capital has increased by SEK 2,307,242, from SEK 28,946,300 to SEK 31,253,542.

For further information, please contact:

Per Andersson Chief Executive Officer Xspray Pharma AB Mob: +46 (0) 70 688 23 48 E-mail: per.andersson@xspray.com

About Xspray Pharma

Xspray Pharma AB (publ) is a pharmaceutical company with numerous product candidates in clinical development, utilizing its innovative, patented HyNap-technology to create improved versions of marketed protein kinase inhibitors (PKI), the largest oncology segment often with high drug prices. The company's goal is to become a market leader of enhanced PKIs for cancer treatment. Xspray Pharma's primary drug candidate, Dasynoc (XS004-dasatinib), is currently undergoing FDA review. It is an amorphous form of dasatinib, demonstrating bioequivalence at a 30% lower dose because of better solubility profile. Its compatibility with proton pump inhibitors (PPIs), commonly co-prescribed to chronic myeloid leukemia patients, provides a significant advantage. Xspray Pharma is building a robust product portfolio, including XS003-nilotinib (an optimized version of Tasigna®) and XS008-axitinib (an optimized version of Inlyta®).

Xspray Pharma's shares are traded at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY). www.xspraypharma.com

This information is information that Xspray Pharma AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023- 12-29 08:00 CET.

Attachments

New number of shares and votes in Xspray Pharma